NICE Backs AbbVie’s Elahere for 270 UK Ovarian Cancer Patients as Appraisal Rules Shift
Updated
Updated · Reuters · Jun 3
NICE Backs AbbVie’s Elahere for 270 UK Ovarian Cancer Patients as Appraisal Rules Shift
3 articles · Updated · Reuters · Jun 3
Summary
About 270 NHS patients in England with platinum-resistant ovarian cancer will gain access to Elahere in the first year, after NICE recommended the drug for routine use beyond trials, private care or compassionate access.
The decision follows NICE’s revised value-assessment framework, changed under a broader UK-U.S. deal that paired zero tariffs on British pharma exports with higher UK drug spending and looser cost-effectiveness criteria.
Elahere will be paid for first through the Cancer Drugs Fund, then move into routine commissioning 90 days after final guidance; eligibility is projected to rise to about 420 patients by year three.
In a 453-patient late-stage trial, the antibody-drug conjugate extended average survival to 16.9 months from 13.3 months on chemotherapy and delayed disease progression to 5.6 months from nearly four months.
NICE said the once-every-three-weeks therapy offers a more manageable side-effect profile than chemotherapy, marking the first additional ovarian cancer option at this stage of disease in more than 20 years.
This 'biological missile' offers new hope, but what's next for the 60% of patients it cannot target?
With a 4-month survival gain, how do we truly measure the value of a drug that transforms quality of life?
As targeted drugs create unique side effects, how must healthcare adapt to these new patient care challenges?
NHS Approves Elahere: A Targeted Breakthrough for Platinum-Resistant Ovarian Cancer Patients
Overview
The NHS in England has approved Elahere (mirvetuximab soravtansine), a targeted therapy for women with platinum-resistant ovarian cancer who have had very limited treatment options. This decision by NICE is especially important because conventional chemotherapy has been burdensome and often ineffective for these patients. Elahere works by precisely attacking cancer cells that are positive for folate receptor-alpha, offering a new and focused treatment approach. The approval marks a major step forward, giving hope to women who have faced scarce effective therapies and improving the outlook for those with this challenging form of ovarian cancer.